Department of Ophthalmology, Hinduhridaysamrat Balasaheb Thackeray Medical College and Dr Rustom Narsi Cooper Municipal General Hospital, Mumbai, Maharashtra, India.
Division of Allergic Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
BMJ Case Rep. 2022 Aug 9;15(8):e247893. doi: 10.1136/bcr-2021-247893.
India saw an unprecedented and rapid rise of invasive coronavirus-associated mucormycosis (CAM) during the delta COVID-19 surge. There is little known about the pathophysiology and if there is a direct causation between the COVID-19 infection and invasive CAM. While the traditional risk factors such as uncontrolled diabetes and other immunocompromising conditions are recognised, there could be several COVID-19-induced phenomena that may predispose the patients to develop CAM and are yet unrecognised. It has been proposed that prior severe COVID-19 is associated with invasive CAM. This could be due to the increased use of immunomodulators or the direct effects of the COVID-19 infection. We report four patients with CAM during the delta surge who did not have prior known COVID-19 infection but on subsequent testing had positive antibodies suggesting past asymptomatic infection. We report the quantitative abnormalities in lymphocyte subsets in all four patients and report CD19+ B cell lymphopenia and reduced percentage of CD27+ CD45RA+ naïve helper T cells. CAM may occur in patients after asymptomatic COVID-19 infection, in the absence of systemic corticosteroid and immunomodulator use, and may reflect underlying immune abnormalities possibly attributable to or unmasked by prior COVID-19 infection.
在 delta 新冠疫情期间,印度出现了前所未有的侵袭性冠状病毒相关毛霉菌病(CAM)的快速上升。对于 COVID-19 感染与侵袭性 CAM 之间是否存在直接因果关系,其病理生理学知之甚少。虽然人们认识到传统的危险因素,如未控制的糖尿病和其他免疫功能低下的情况,但可能有一些 COVID-19 引起的现象可能使患者易患 CAM,但尚未被认识到。有人提出先前严重的 COVID-19 与侵袭性 CAM 有关。这可能是由于免疫调节剂的使用增加,或者 COVID-19 感染的直接影响。我们报告了在 delta 激增期间出现 CAM 的四名患者,他们之前没有已知的 COVID-19 感染,但随后的抗体检测呈阳性,表明过去有过无症状感染。我们报告了所有四名患者淋巴细胞亚群的定量异常,并报告了 CD19+ B 细胞淋巴细胞减少症和 CD27+ CD45RA+幼稚辅助 T 细胞百分比降低。CAM 可能发生在无症状 COVID-19 感染后的患者中,在没有使用全身皮质类固醇和免疫调节剂的情况下,可能反映了潜在的免疫异常,这些异常可能归因于或由先前的 COVID-19 感染引起或揭示。